medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-13-24-27medsovet-1356Research ArticleАРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯARTERIAL HYPERTENSIONТрехкомпонентная антигипертензивная терапия. Перспективы примененияTHREE-COMPONENT ANTI-HYPERYTENSION THERAPY – PROSPECTS OF APPLICATIONЧУКАЕВАИ. И.CHUKAEVAI. I.

д.м.н., профессор

Москва

MD, Prof.

Moscow

АХМАТОВАФ. Д.AKHMATOVAF. D.

к.м.н.

Москва

PhD in medicine

Moscow

СПИРЯКИНАЯ. Г.SPIRYAKINAY. G.

к.м.н.

Москва

PhD in medicin

Moscow

Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian Federation2016301220160132427Copyright © ЧУКАЕВА И.И., АХМАТОВА Ф.Д., СПИРЯКИНА Я.Г., 20162016ЧУКАЕВА И.И., АХМАТОВА Ф.Д., СПИРЯКИНА Я.Г.CHUKAEVA I.I., AKHMATOVA F.D., SPIRYAKINA Y.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1356

Широкая распространенность артериальной гипертонии (АГ) – до 40% всей популяции (а среди пожилых пациентов выше 50%) – делает ее одной из самых важных проблем современной медицины. В докладе Всемирной организации здравоохранения АГ названа первой причиной смертности во всем мире [3]. Определяющее значение в улучшении прогноза по ССО у больных АГ принадлежит снижению повышенного артериального давления и достижению его целевого уровня.

The high prevalence of arterial hypertension (AH) – up to 40% of the whole population (and more than 50% among elderly patients) – makes it one of the most important problems of the modern medicine. In the report of the World Health Organization AH is called the first reason of mortality worldwide [3]. Reduction of increased arterial hypertension and achievement of its target value are of paramount importance for improvement of the forecast by cardiovascular complications in AH patients.

артериальная гипертонияартериальное давлениетрехкомпонентная антигипертензивная терапияамлодипининдапамидпериндоприлarterial hypertensionarterial pressurethree-component anti-hypertension therapyamlodipineindapamideperindoprilReferencesКобалава Ж.Д., Котовская Ю.В., Троицкая Е.А. Комбинированная терапия артериальной гипертонии: роль трехкомпонентных комбинаций. Кардиология, 2011, 6: 84-90./Kobalava Z.D., Kotovskaya Y.V., Troitskaya E.A. Combined therapy of arterial hypertension: role of three-component combinations. Kardiologia, 2011, 6: 84-90.Кобалава Ж.Д., Котовская Ю.В., Троицкая Е.А. Комбинированная терапия артериальной гипертонии: роль трехкомпонентных комбинаций. Кардиология, 2011, 6: 84-90./Kobalava Z.D., Kotovskaya Y.V., Troitskaya E.A. Combined therapy of arterial hypertension: role of three-component combinations. Kardiologia, 2011, 6: 84-90.Муромцева Г.А., Концевая А.В., Константинов В.В. и соавт. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 г. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика, 2014, 13(6): 4-11. / Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V. et al. Distribution of risk factors of noninfectious diseases in the Russian population in 2012-2013. Results of study ESSE-RF. Kardiovaskulyarnaya Terapia I Profilaktika, 2014, 13 (6): 4-11.Муромцева Г.А., Концевая А.В., Константинов В.В. и соавт. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 г. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика, 2014, 13(6): 4-11. / Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V. et al. Distribution of risk factors of noninfectious diseases in the Russian population in 2012-2013. Results of study ESSE-RF. Kardiovaskulyarnaya Terapia I Profilaktika, 2014, 13 (6): 4-11.Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet, 2002, 360: 1347-1360.Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet, 2002, 360: 1347-1360.Mancia G, Ambrosioni E, Agabiti-Rosei E, Leonetti G, Trimarco B, Volpe M. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens,. 2005 Aug, 23(8): 1575-81.Mancia G, Ambrosioni E, Agabiti-Rosei E, Leonetti G, Trimarco B, Volpe M. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens,. 2005 Aug, 23(8): 1575-81.Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta–blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens, 2001, 14: 241-247.Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta–blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens, 2001, 14: 241-247.Dahlof B, Sever PS, Poulter NR, Wedel H et all. ASCOT Investigators. ASCOT-BPLA: a multicentre randomized controlled trial. Lancet, 2005, 366: 895-906. RT 1174. Journal of Hypertension, 2007, 25(6).Dahlof B, Sever PS, Poulter NR, Wedel H et all. ASCOT Investigators. ASCOT-BPLA: a multicentre randomized controlled trial. Lancet, 2005, 366: 895-906. RT 1174. Journal of Hypertension, 2007, 25(6).Chobanian AV, Bakris GL, Black HR et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42(6): 1206-1252.Chobanian AV, Bakris GL, Black HR et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42(6): 1206-1252.Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC). J. Hypertens., 2007, 25: 1105-1187.Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC). J. Hypertens., 2007, 25: 1105-1187.Mancia G, Fagard R, Narkiewicz K et al. 2013 Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC). J. Hypertens., 2013, 31: 1281-1357.Mancia G, Fagard R, Narkiewicz K et al. 2013 Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC). J. Hypertens., 2013, 31: 1281-1357.Gradman A. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens, 2010, 12: 869-878.Gradman A. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens, 2010, 12: 869-878.Scheen AJ, Legrand V. L’étude EUROPA: protection cardio-vasculaire avec le périndopril chez les patients avec coronaropathie stable. Rev Med Liège, 2003, 58: 713-716.Scheen AJ, Legrand V. L’étude EUROPA: protection cardio-vasculaire avec le périndopril chez les patients avec coronaropathie stable. Rev Med Liège, 2003, 58: 713-716.Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother, 2012, 13: 1515-1526.Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother, 2012, 13: 1515-1526.Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood PressControl, 2014, 7: 35-47.Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood PressControl, 2014, 7: 35-47.Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med, 2003, 115: 41-46.Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med, 2003, 115: 41-46.Mancia G et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J of Hypertens, 2013, 31: 1281-1357.Mancia G et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J of Hypertens, 2013, 31: 1281-1357.Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, 2004, 363: 2049-2051.Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, 2004, 363: 2049-2051.Mancia G, Messerli F, Bakris G et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension, 2007, 50: 299-305.Mancia G, Messerli F, Bakris G et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension, 2007, 50: 299-305.http://www.diet.com/g/national-health-andnutrition- examination-survey-nhanes.http://www.diet.com/g/national-health-andnutrition- examination-survey-nhanes.Peterson JC, Adler S, Burkart JM et al for the Modification of Diet in Renal Disease Study Group. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med, 1995, 123: 754-762.Peterson JC, Adler S, Burkart JM et al for the Modification of Diet in Renal Disease Study Group. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med, 1995, 123: 754-762.Lithell H et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens, 2003, 21: 875-886.Lithell H et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens, 2003, 21: 875-886.Pepine J et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized cоntrolled tial. JAMA, 2003, 290: 2805-2816.Pepine J et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized cоntrolled tial. JAMA, 2003, 290: 2805-2816.Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs, 2014, 14: 137- 145.Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs, 2014, 14: 137- 145.Páll D, Szántó I, Szabó Z. Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of Treatment with Perindopril, Amlodipine, and Indapamide SR. Clin Drug Investig, 2014, 34(10): 701-708.Páll D, Szántó I, Szabó Z. Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of Treatment with Perindopril, Amlodipine, and Indapamide SR. Clin Drug Investig, 2014, 34(10): 701-708.

The authors declare that there are no conflicts of interest present.